CAMBRIDGE, Mass., Jan. 02, 2018 -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases, today announced that management will present at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 8th at 1:30 p.m. ET / 10:30 a.m. PT. Following the presentation there will be a Q&A session starting at 2:00 p.m. ET / 11:00 a.m. PT.
The presentation and Q&A session will be webcast live under the investor relations section of Sarepta’s website at www.sarepta.com and will be archived there following the presentation and Q&A session for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.
About Sarepta Therapeutics
Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates. For more information, please visit www.sarepta.com.
Internet Posting of Information
We routinely post information that may be important to investors in the 'For Investors' section of our website at www.sarepta.com. We encourage investors and potential investors to consult our website regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors:
Sarepta Therapeutics, Inc.
Ian Estepan, 617-274-4052
[email protected]
or
W2O Group
Brian Reid, 212-257-6725
[email protected]


Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan
FTC Questions Apple News Over Alleged Bias Against Conservative Media
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates
How Marco Pharma International Preserves German Homeopathic Traditions in America
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App
Converse Cuts Corporate Jobs as Nike Restructures to Revive Sales Growth
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks
Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings
Gates Foundation Denies Financial Ties to Jeffrey Epstein Following DOJ Email Release
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 



